StockData

Advanced Biomed vs Sera Prognostics

ADVB and SERA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADVB and SERA compare

Sera Prognostics is the larger company, worth 14 times as much as Advanced Biomed ($78.1M against $5.5M).

Advanced Biomed scores higher on the StockData Score (8 against 5 for Sera Prognostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADVBSERA
Size and price
Market cap$5.5M$78.1M
Share price$3.31$1.98
Change, 1 year−61.7%−26.4%
Change, 5 years–−81.7%
Beta (5Y)1.151.22
Employees12–
StockData Score
Total score8 (better)5
Valuation score2 (better)1
Growth score00
Performance score1 (better)0
Health score5 (better)4
Dividend score00
Valuation
P/E0.6×–
P/S–814×
P/B0.5× (better)1.5×
FCF yield–−37.1%
Growth
Revenue growth (TTM)–1.1%
Revenue growth, 5Y average–26.5%
Profitability
Operating margin–−38755%
Net margin–−34867%
FCF margin–−30199%
Return on equity85.0% (better)−49.7%
Return on invested capital–−124%
Financial health
Debt / equity0.000.00
Interest coverage–−5315.0×
Current ratio8.09 (better)1.88
Altman Z-score1.61 (better)−5.41
Piotroski F-score44
Dividends and buybacks
Buyback yield–0.00%
Shareholder yield0.00%0.00%
Ownership
Held by institutions–43.2%
Held by insiders0.00%30.4%
Insider net buying, 12 months–−$524K
Short interest, % of float0.68%0.80%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.